Overview

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.
Phase:
Phase 2
Details
Lead Sponsor:
Oncology Institute of Southern Switzerland
Treatments:
Metronidazole